Go KCL
Go KCL
Go KCL
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologi Pharmacodynamics General The use of CNS Before Drug Administration:
Potassium Chloride c or Mechanism of Indication/s: Potassium Chloride - Confusion ● Conduct a thorough history to identify
Classification Action: The use of is contraindicated in - Restlessness any relevant drug allergies.
Trade Name: : Potassium the instance of: - Weakness ● Confirm the patient's status through
- Kaligen Potassium- Maintain acid-base Chloride is - Paresthesia laboratory results, including blood
- K-lyte containing balance,isotonicity indicated for: ● Hypersensitivity tests.
- Kalium preparations and electrophysiologic to potassium Cardiovascular System: ● Obtain baseline vital signs.
- Kaliusaphride balance of the cell. (1) Electrolyte chloride or - Arrhythmias, ● Be cautious of look-alike sound
- K tab Therapeutic Activator in many replenisher components of - ECG changes situations with potassium
Classification: enzymatic reactions; and in the the formulation - Hypotension preparations; ensure verification of
Electrolyte essential to treatment of the correct product before usage and
Minimum Dose: supplement transmission of hypokalemia. ● Patients with Gastrointestinal System avoid switching between products.
40 mEq in 2 divided nerve impulses; renal failure, and - Abdominal pain
doses daily Pregnancy contraction of Patient’s in those with - Diarrhea During Drug Administration:
Category cardiac, skeletal, Indication: conditions in - Flatulence ● Double-check and validate the
Maximum Dose: Risk: C and smooth muscle; - treatment of which potassium - Nausea doctor's order.
200 mEq daily gastric secretion; renal hypokalemia retention is - Vomiting, ● Administer medication with or after
function; tissue present - GI ulceration meals, accompanied by a full glass of
Patient’s Dose: synthesis; and water or fruit juices to prevent
10 mEq tablet/ 1 tab carbohydrate ● Use cautiously Others gastrointestinal distress.
TID metabolism. in patients with Hyperkalemia ● Instruct the patient not to chew tablets
cardiac disease, but to swallow them whole.
Route: Oral renal
impairment,and After Drug Administration:
acid base
disorders. ● Document the procedure accurately.
● Monitor vital signs regularly.
● Educate the patient and their
significant other about potential side
effects.
Certification Date: 1 SDF-CON-304-071-00
February 2021
Recertification due
Page 1 of 5
date: 24 January 2024
For verification of the
certificate please
access
www.gcl-intl.com
(Certification check
and type the
registration number)
Pharmacokinetics: ● Encourage them to promptly report
Frequency: Interactions any abnormalities such as weakness,
● TID Excretion nausea, or vomiting.
Renal Captopril: The risk ● Inform the patient about the possibility of
Availability/Form: or severity of detecting wax matrix in stool, indicating
Extended release Half-life hyperkalemia can drug absorption.
tablets 8 hours be increased when
☐ 8 mEq Potassium chloride
☐ 10 mEq Onset is combined with
☐ 20 mEq 60 minutes Captopril.